Latest News on LENZ

Financial News Based On Company


Advertisement
Advertisement

Form 4 LENZ Therapeutics Inc: Daniel R. Chevallard (CFO) For: 30 October

https://ca.investing.com/news/stock-market-news/form-4-lenz-therapeutics-inc-daniel-r-chevallard-cfo-for-30-october-93CH-4927522
This article reports on a Form 4 filing for LENZ Therapeutics Inc., indicating a transaction involving Daniel R. Chevallard, the company's CFO, on October 30. The filing, published on November 3, 2026, highlights insider trading activity for the company.

Form 13D/A LENZ THERAPEUTICS For: 2 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-13da-lenz-therapeutics-for-2-november-93CH-4923677
This article announces the filing of Form 13D/A for LENZ THERAPEUTICS on November 2nd. The content appears to be a standard financial market report from Investing.com, providing basic information about the filing and links to further market data. It primarily serves as a notification of the regulatory filing.

Form 4 LENZ Therapeutics Inc: RA CAPITAL MANAGEMENT, L.P. (10% Owner) For: 29 October

https://ca.investing.com/news/stock-market-news/form-4-lenz-therapeutics-inc-ra-capital-management-lp-10-owner-for-29-october-93CH-4923652
The article reports on a Form 4 filing for LENZ Therapeutics Inc, indicating that RA CAPITAL MANAGEMENT, L.P. is a 10% owner. The filing pertains to activities on October 29. This information is relevant for investors tracking insider transactions and significant ownership changes in LENZ Therapeutics.

At $3.36 a share on average, RA Capital funds sell LENZ Therapeutics (LENZ) stock.

https://www.stocktitan.net/sec-filings/LENZ/form-4-lenz-therapeutics-inc-insider-trading-activity-264fbb1b1345.html
RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund II, L.P., and a separately managed account sold a combined 2.72 million shares of LENZ Therapeutics common stock on October 29, 2026. The shares were sold at a weighted-average price of $3.36 per share, with transactions ranging from $3.16 to $3.58. This insider trading activity is documented in a Form 4 filing with the SEC.

LENZ Therapeutics, Inc. (LENZ) Q3 FY2026 earnings call transcript

https://finance.yahoo.com/quote/LENZ/earnings/LENZ-Q3-2026-earnings_call-730270.html
LENZ Therapeutics reported over 50% sequential growth in Q3 2026 product revenue and total VIZZ prescriptions, driven by consumer marketing and a new telehealth channel. The company announced a strategic reorganization to focus on consumer-led commercial strategy, aiming for a 50%+ reduction in operating expenses and targeting $70M-$75M OpEx in 2027, with over 70% allocated to marketing. CEO Eef Schimmelpennink also announced his transition, with CFO Dan Chevallard stepping in as interim CEO.
Advertisement

LENZ: Q3 growth accelerates as strategy pivots to consumer marketing and lower costs

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4383238:0-lenz-q3-growth-accelerates-as-strategy-pivots-to-consumer-marketing-and-lower-costs/
LENZ Therapeutics, Inc. (LENZ) experienced over 50% quarter-over-quarter growth in Q3 product revenue and prescriptions, driven by telehealth and consumer advertising. The company is reorganizing to prioritize consumer marketing, aiming for $70 million-$75 million in 2027 operating expenses, alongside a CEO transition. This information is based on the LENZ Therapeutics, Inc. Q3 2026 Audio Transcript from October 29, 2026.

Earnings call transcript: LENZ Therapeutics misses Q3 2026 estimates as VIZZ grows

https://www.investing.com/news/transcripts/earnings-call-transcript-lenz-therapeutics-misses-q3-2026-estimates-as-vizz-grows-93CH-4984009
LENZ Therapeutics reported a wider-than-expected third-quarter loss and lower revenue than Wall Street estimates, but its presbyopia eye drop, VIZZ, showed significant growth with product revenue and prescriptions increasing over 50% sequentially. The company announced a major reorganization to cut operating expenses by more than 50% and shift focus to consumer marketing, while CEO Afschin Skjalm Paddock will step down. Despite missing headline numbers, the stock saw a modest gain, indicating investors are weighing commercial growth and cost-cutting plans against the financial miss.

LENZ Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62695988/lenz-therapeutics-q3-2026-earnings-call-transcript
LENZ Therapeutics reported over 50% growth in Q3 2026 product revenue and prescriptions, driven by consumer-focused initiatives and telehealth, which contributed over half of incremental scripts. The company is reorganizing to emphasize consumer marketing and reduce operating expenses by over 50% to $70-75 million in 2027. CEO Eef Schimmelpennink will step down by December 2026, with CFO Dan Chevallard appointed as Interim CEO.

LENZ Therapeutics, Inc. Stock 12‑Month Price Target Raised to $21.43, Implies 568% Upside

https://www.tradingview.com/news/tradingview:e2ed700193270:0-lenz-therapeutics-inc-stock-12-month-price-target-raised-to-21-43-implies-568-upside/
The average 12-month price target for LENZ Therapeutics, Inc. stock has been raised from $20 to $21.43 by 7 analysts, implying a potential upside of approximately 568% from the Oct. 28 closing price. The consensus rating for LENZ Therapeutics, Inc. remains "Buy," with 5 Buy ratings and 2 Holds.

LENZ Therapeutics, Inc. Stock 12‑Month Price Target Raised to $21.43, Implies 568% Upside

https://www.tradingview.com/news/tradingview:e2ed700193270:0-lenz-therapeutics-inc-stock-12-month-price-target-cut-to-19-17-implies-497-upside/
LENZ Therapeutics, Inc.'s average 12-month price target has increased from $20 to $21.43, according to estimates from 7 analysts, implying a potential upside of 568% from the Oct. 28 closing price. The consensus rating for the stock remains a "Buy," with 5 buy recommendations and 2 holds.
Advertisement

Form 8K LENZ Therapeutics Inc For: 28 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-lenz-therapeutics-inc-for-28-october-93CH-4911012
This article from Investing.com announces that LENZ Therapeutics Inc. filed a Form 8K on October 28, 2026. The filing is a standard regulatory disclosure used by companies to report significant events that investors should know about. No specific details of the 8K filing are provided in the article itself.

LENZ Therapeutics names Daniel Chevallard interim CEO as Evert Schimmelpennink exits

https://www.tradingview.com/news/tradingview:fa68f247118cf:0-lenz-therapeutics-names-daniel-chevallard-interim-ceo-as-evert-schimmelpennink-exits/
LENZ Therapeutics announced that Evert Schimmelpennink will depart from his roles as President, CEO, and board member on December 1, 2026. Current CFO Daniel Chevallard will assume the interim President and CEO positions on the same date. The company is implementing retention agreements for key officers following a reorganization.

LENZ Therapeutics, Inc. (LENZ) Misses Q3 EPS by 8c

https://www.streetinsider.com/Earnings/LENZ+Therapeutics%2C+Inc.+%28LENZ%29+Misses+Q3+EPS+by+8c/27250160.html
LENZ Therapeutics, Inc. (LENZ) reported a Q3 EPS of ($0.99), missing the analyst estimate of ($0.91) by $0.08. The company also missed revenue expectations, reporting $3.38 million against a consensus estimate of $4.5 million. This financial performance update highlights a significant shortfall in both earnings per share and revenue for the quarter.

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

https://ir.lenz-tx.com/news-events/press-releases/detail/63/lenz-therapeutics-reports-third-quarter-2026-financial-results-announces-strategic-consumer-marketing-focused-reorganization-and-ceo-succession
LENZ Therapeutics announced its Q3 2026 financial results, reporting a 50% increase in VIZZ product sales over the prior quarter and strong momentum into Q4. The company is undergoing a strategic reorganization to prioritize consumer marketing, aiming to reduce 2027 annual operating expenses by over 50%. Additionally, Eef Schimmelpennink will transition from his role as President and CEO on December 1, 2026, with Dan Chevallard appointed as Interim President and CEO.

LENZ Therapeutics, Inc. Estimates – NASDAQ:LENZ

https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-estimates/
The article provides an overview of LENZ Therapeutics, Inc. (NASDAQ: LENZ) financial data and analyst estimates, accessible through TradingView. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across income statements, balance sheets, and cash flow statements. The platform also visualizes trends over time for both annual and quarterly data.
Advertisement

LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

https://finance.yahoo.com/healthcare/articles/lenz-therapeutics-report-third-quarter-120000140.html
LENZ Therapeutics, Inc. announced it will report its third quarter 2026 financial results on Thursday, October 29, 2026, at 8:30 a.m. EDT. The company will host a webcast and conference call for investors to discuss the results. LENZ Therapeutics focuses on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, an FDA-approved eye drop for presbyopia.

LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

https://ir.lenz-tx.com/news-events/press-releases/detail/62/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026
LENZ Therapeutics, Inc. announced it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results. Investors can participate via telephone or a live webcast available on the company's website. LENZ Therapeutics is focused on commercializing VIZZ® (aceclidine ophthalmologic solution) 1.44% for the treatment of presbyopia.

LENZ Therapeutics Is Maintained at Buy by TD Cowen

https://www.moomoo.com/news/post/1001889641/lenz-therapeutics-is-maintained-at-buy-by-td-cowen
TD Cowen has maintained its "Buy" rating on LENZ Therapeutics. The article also briefly mentions Unity Software's fourth-quarter financial results, reporting a 35% year-over-year revenue increase to $609 million, surpassing estimates, and a quarterly loss of 66 cents per share.

TD Cowen maintains Buy rating on LENZ Therapeutics, $50 price target

https://www.tradingview.com/news/tradingview:d613c084320cf:0-td-cowen-maintains-buy-rating-on-lenz-therapeutics-50-price-target/
TD Cowen has reiterated its Buy rating on LENZ Therapeutics's stock, setting a price target of $50.00, which suggests a significant upside of 1467.4% from its recent closing price. The bullish outlook is driven by LENZ Therapeutics's strong market opportunity in treating presbyopia with its product VIZZ, and positive clinical outcomes demonstrating improved near vision and a benign safety profile.

Insiders Re-Evaluate Their US$654.9k Stock Purchase As LENZ Therapeutics Falls To US$113m

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/news/insiders-re-evaluate-their-us6549k-stock-purchase-as-lenz-th
Insiders at LENZ Therapeutics, Inc. (NASDAQ:LENZ) who purchased US$654.9k worth of stock at an average price of US$12.15 are now seeing their investment fall to US$183.2k due to a 10% price decline, as the company's market cap dropped to US$113m. Despite the recent losses, past insider purchases, including a US$251k acquisition by President Evert Schimmelpennink at US$8.95 per share, suggest confidence in the company's future value. Although insider ownership is relatively low at 2.6%, the fact that insiders bought at higher prices than the current US$3.40 share price indicates they might see value at the present level, even though there have been no insider transactions in the last three months.
Advertisement

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

https://www.financialcontent.com/article/gnwcq-2026-10-6-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-lenz-therapeutics-inc-lenz
Pomerantz LLP is investigating LENZ Therapeutics, Inc. (NASDAQ: LENZ) on behalf of investors for potential securities fraud. This investigation follows a sharp drop in Lenz's stock price after Bank of America downgraded the company due to slower-than-expected commercial launch for its eye drop VIZZ, despite reported total revenues that included significant one-time licensing milestones. Investors are advised to contact Pomerantz LLP regarding this matter.

Investigation launched into LENZ Therapeutics over possible securities fraud after weak sales report.

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-selidiki-tuntutan-pemegang-saham-lenz-therapeutics
Pomerantz LLP has initiated an investigation into LENZ Therapeutics following its weaker-than-expected Q2 2026 results, which showed flat organic sales for its VIZZ eye drop product and revenue primarily from one-time licensing deals. This led to a downgrade by Bank of America and a sharp drop in LENZ's stock price. The investigation will determine if LENZ and its executives engaged in securities fraud or unlawful practices, potentially paving the way for legal action and compensation for affected shareholders.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

https://www.financialcontent.com/article/gnwcq-2026-9-22-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-lenz-therapeutics-inc-lenz
Pomerantz LLP is investigating LENZ Therapeutics, Inc. (NASDAQ: LENZ) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows Lenz's August 11, 2026, financial report, which revealed weak organic product sales for its primary eye drop, VIZZ, leading to a significant stock downgrade by Bank of America. Investors are advised to contact the law firm for more information regarding joining a potential class action.

LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/lenz-therapeutics-inc.-lenz-investigation-bronstein-gewirtz-and-1213027
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against LENZ Therapeutics, Inc. (LENZ) following a significant drop in its stock price. This decline occurred after the company reported disappointing Q2 2026 financial results, with organic product sales of its VIZZ eye drop coming in flat, and Bank of America subsequently downgrading the stock and lowering its price target due to a slower-than-expected commercial launch. The firm encourages investors who purchased LENZ securities to contact them for more information regarding the investigation.

LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz

https://natlawreview.com/press-releases/lenz-therapeutics-inc-lenz-investigation-bronstein-gewirtz-grossman-llc
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of LENZ Therapeutics, Inc. (NASDAQ: LENZ) after the company reported disappointing Q2 2026 financial results, with primary commercial eye drop VIZZ sales coming in flat. Following this, Bank of America downgraded LENZ stock, causing its price to fall sharply. The law firm encourages affected shareholders to contact them to learn more about the investigation.
Advertisement

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against LENZ Therapeutics, Inc. (LENZ) and Encourages Stockholders to Learn More About the Investigation

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1213018
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into LENZ Therapeutics, Inc. (LENZ) following a significant drop in its stock price. This investigation comes after LENZ reported second-quarter financial results, where organic product sales for its eye drop, VIZZ, were flat, and Bank of America downgraded the stock due to a slower-than-expected commercial launch. The firm encourages affected investors to join their class action lawsuit.

LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ...

https://finance.yahoo.com/healthcare/articles/lenz-therapeutics-inc-lenz-q2-050206631.html
LENZ Therapeutics Inc. (LENZ) reported its Q2 2026 earnings, highlighting a 45% month-over-month increase in VIZZ prescriptions in July due to national TV advertising and telehealth launch. The company achieved $5.5 million in total revenue, including $1.7 million from product sales, and maintains a strong cash position of $220 million. Despite strong patient persistence in e-pharmacy, retail channel uptake remains low, and the company is evaluating commercial initiatives to drive sustainable growth.

Blue Owl Capital Holdings LP Invests $4.30 Million in LENZ Therapeutics, Inc. $LENZ

https://www.marketbeat.com/instant-alerts/filing-blue-owl-capital-holdings-lp-invests-430-million-in-lenz-therapeutics-inc-lenz-2026-08-21/
Blue Owl Capital Holdings LP has acquired a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ), purchasing 756,722 shares valued at approximately $4.30 million. This investment represents about 2.41% of LENZ Therapeutics and 0.6% of Blue Owl's portfolio. Despite LENZ shares trading near their one-year low, institutional ownership remains significant at 54.32%, and analysts hold a "Moderate Buy" consensus with an average price target of $28.80.

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/stocks/LENZ-Q/pressreleases/3930354/lenz-therapeutics-lenz-q2-2026-earnings-call-transcript/
LENZ Therapeutics (NASDAQ:LENZ) reported its Q2 2026 earnings, detailing modest growth but significant increases in prescription starts during July following the launch of a telehealth platform and a national advertising campaign. The company highlighted strong patient persistence with over 60% of e-pharmacy patients repurchasing VIZZ, and an average annualized purchase rate of five monthly packs per patient. LENZ is expanding its global commercial footprint with five international partnerships and nine regulatory submissions under review, aiming for sustained patient growth and disciplined capital allocation.

LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research

https://www.marketbeat.com/instant-alerts/lenz-therapeutics-nasdaqlenz-stock-rating-upgraded-by-zacks-research-2026-08-15/
Zacks Research has upgraded LENZ Therapeutics (NASDAQ:LENZ) from a "strong sell" to a "hold" rating, though other analysts remain divided, resulting in an overall "Moderate Buy" rating with an average price target of $28.80. The company's stock rose 2.8% to $4.73, while it reported better-than-expected quarterly results with a loss of $1.02 per share and revenue of $5.49 million, surpassing analyst estimates. Despite beating expectations, LENZ continues to post substantial losses, with analysts forecasting a full-year loss of $4.18 per share.
Advertisement

Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83

https://www.sahmcapital.com/news/content/earnings-release-heres-why-analysts-cut-their-lenz-therapeutics-inc-nasdaqlenz-price-target-to-us2683-2026-08-14
Analysts have cut LENZ Therapeutics, Inc.'s revenue estimates for 2026 and reduced their price target to US$26.83, despite lowering loss estimates. While the company beat revenue estimates in its latest report, future revenue is expected to decline significantly, underperforming the broader industry. This shift indicates increased pessimism regarding the company's intrinsic value.

Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/news/earnings-release-heres-why-analysts-cut-their-lenz-therapeut
Analysts have revised down their revenue estimates for LENZ Therapeutics, Inc. for 2026 to US$17.0m, a significant 21% decline, despite beating recent revenue estimates. Although loss estimates were reduced, the consensus price target for LENZ Therapeutics was cut by 16% to US$26.83, reflecting pessimism due to the revenue downgrade and expected underperformance compared to the broader industry. The wide range of analyst price targets suggests difficulty in accurately valuing the company's future.

Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ)

https://seekingalpha.com/news/4632587-lenz-stock-drops-bank-america-downgrades
Lenz Therapeutics' stock fell for the third straight day after Bank of America downgraded the company from Buy to Neutral. The downgrade was attributed to a slower-than-expected launch of its presbyopia therapy, VIZZ. Analyst Jason Gerberry also lowered his price target for LENZ.

BofA downgrades Lenz Therapeutics stock rating on slow launch

https://m.investing.com/news/analyst-ratings/bofa-downgrades-lenz-therapeutics-stock-rating-on-slow-launch-93CH-4856020?ampMode=1
BofA Securities downgraded LENZ Therapeutics Inc. (NASDAQ:LENZ) from Buy to Neutral and cut its price target significantly, citing a slower-than-expected launch of its VIZZ presbyopia eye drops. Despite some positive financial results in Q2 2026, including a revenue beat, the firm expressed concerns about the company's cash burn and path to profitability, now valuing the stock primarily on its cash position. This downgrade comes amidst modest prescription-volume growth for VIZZ, leading BofA to reduce its near-term and peak sales forecasts.

LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $29.86, Implies 473% Upside

https://www.tradingview.com/news/tradingview:6e73f9a28f7c6:0-lenz-therapeutics-inc-stock-12-month-price-target-cut-to-29-86-implies-473-upside/
Analysts have revised the average 12-month price target for LENZ Therapeutics, Inc. (LENZ) stock down to $29.86 from $32, with individual forecasts ranging from $7 to $60 per share. Despite the cut, this new target still suggests a substantial 473% potential upside from its August 11 closing price. The consensus rating for LENZ remains a "Buy" among the 7 covering analysts.
Advertisement

Over 60% of LENZ’s VIZZ ePharmacy Patients Bought Multiple Packs

https://www.stocktitan.net/news/LENZ/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-llc8l7sjzg2q.html
LENZ Therapeutics reported Q2 2026 total revenue of $5.5 million, with VIZZ product sales reaching $1.7 million from approximately 27,000 packs. The company highlighted strong early adoption for VIZZ, noting that over 60% of ePharmacy patients purchased multiple monthly packs, tracking to about five packs annually in early cohorts. LENZ also expanded its international presence with new agreements in Australia/New Zealand, Canada, Greater China, and Saudi Arabia, while reporting a net loss of $31.9 million for the quarter.

LENZ Therapeutics (NASDAQ:LENZ) Issues Earnings Results, Beats Estimates By $0.03 EPS

https://www.marketbeat.com/instant-alerts/lenz-therapeutics-nasdaqlenz-issues-earnings-results-beats-estimates-by-003-eps-2026-08-11/
LENZ Therapeutics (NASDAQ:LENZ) reported its quarterly earnings, beating analyst estimates by $0.03 EPS with a loss of $1.02 per share and revenue of $5.49 million, significantly exceeding expectations. Despite commercial momentum and increased prescription sales, the company posted a $31.9 million net loss, and its stock declined by 2.8%. Analysts currently hold a "Hold" rating with an average price target of $29.80 for the stock.

Earnings call transcript: LENZ Therapeutics tops Q2 2026 forecasts as sales jump

https://m.investing.com/news/transcripts/earnings-call-transcript-lenz-therapeutics-tops-q2-2026-forecasts-as-sales-jump-93CH-4852804?ampMode=1
LENZ Therapeutics exceeded Q2 2026 financial forecasts, reporting a narrower loss of $1.02 per share and revenue of $5.5 million, significantly beating analyst expectations. The positive results were driven by strong early adoption of its presbyopia eye drop, VIZZ, including a 45% month-over-month increase in July prescriptions, supported by new telehealth options and national TV advertising. The company emphasized VIZZ's high refill rates compared to competitors, its strong cash position, and plans for disciplined capital allocation to sustain growth and global expansion.

LENZ Therapeutics (LENZ) grows VIZZ sales but posts $31.9M Q2 loss

https://www.stocktitan.net/sec-filings/LENZ/10-q-lenz-therapeutics-inc-quarterly-earnings-report-308576926eb4.html
LENZ Therapeutics reported a Q2 2026 net loss of $31.9 million despite generating $5.5 million in total revenue, driven by VIZZ product sales and ex-U.S. licensing agreements. The company's net loss was primarily due to increased selling, general, and administrative expenses as it expanded commercial activities for its FDA-approved presbyopia eye drop, VIZZ. LENZ believes its current liquidity of $220.0 million will fund operations for at least 12 months as it continues to commercialize VIZZ and seek international partnerships.

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

https://ir.lenz-tx.com/news-events/press-releases/detail/61/lenz-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights
LENZ Therapeutics reported strong Q2 2026 financial results with $5.5 million in total revenue from VIZZ product sales and global license agreements. The company highlighted accelerating VIZZ prescription growth through its new telehealth channel and strong patient persistence, with over 60% of ePharmacy patients purchasing multiple monthly packs. LENZ also expanded its global commercialization strategy with new international partnerships and regulatory submissions for VIZZ.
Advertisement

LENZ’s VIZZ Launch Puts Presbyopia Sales Under The Microscope

https://finimize.com/content/lenz-asset-snapshot
LENZ Therapeutics (Nasdaq: LENZ) is set to report its Q2 2026 earnings on August 11th, with investors keenly focused on the commercial success of its presbyopia eye-drop, VIZZ (LNZ100). The company's stock has significantly underperformed the broader market, dropping around 83% over the past year, reflecting market concerns about execution risk and commercial adoption. The article details the bull and bear cases, highlighting the high-risk, high-optionality nature of LENZ as it navigates the competitive presbyopia market and aims to turn early prescription momentum into sustainable revenue and profitability.

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

https://ca.finance.yahoo.com/news/lenz-therapeutics-report-second-quarter-200500178.html
LENZ Therapeutics announced it will host a webcast on August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights. The company is focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, an FDA-approved eye drop for presbyopia. A replay of the webcast will be available on the company's website.

LENZ Therapeutics Sets Webcast on Its FDA-Approved Eye Drop

https://www.stocktitan.net/news/LENZ/lenz-therapeutics-to-report-second-quarter-2026-financial-results-eqncgjpb1a39.html
LENZ Therapeutics announced it will host a webcast on August 11, 2026, to discuss its second-quarter 2026 financial results and recent corporate highlights. The webcast will feature discussions on VIZZ® (aceclidine ophthalmologic solution) 1.44%, the company's FDA-approved eye drop for presbyopia. The announcement follows a moderate positive market reaction to LENZ's previous earnings report.

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

https://ir.lenz-tx.com/news-events/press-releases/detail/60/lenz-therapeutics-to-report-second-quarter-2026-financial-results-and-recent-corporate-highlights-on-august-11-2026
LENZ Therapeutics, Inc. announced it will host a webcast on August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights. The pharmaceutical company, focused on commercializing VIZZ® (aceclidine ophthalmologic solution) 1.44% for presbyopia, will provide details for accessing the conference call and live webcast. A replay will be available on their website for 30 days.

LENZ Therapeutics Inc (LENZ) - Tradingkey Stock Score & Comprehensive Stock Analysis

https://www.tradingkey.com/markets/stocks/lenz/stock-analysis
This article provides a comprehensive stock analysis and "TradingKey Stock Score" for LENZ Therapeutics Inc (LENZ). It highlights the company's strong fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. The analysis also covers institutional ownership, analyst ratings, and the company's product pipeline including LNZ100 and LNZ101 for presbyopia treatment.
Advertisement

LENZ Therapeutics Inc (LENZ) Shareholder Structure: Major Shareholders & Institutional Holdings

https://www.tradingkey.com/markets/stocks/lenz/ownership
This article details the shareholder structure of LENZ Therapeutics Inc (LENZ), listing its major shareholders and their proportions, such as RA Capital Management, LP (13.33%) and Fidelity Management & Research Company LLC (11.81%). It also categorizes shareholder types, including Investment Advisor (42.54%) and Venture Capital (33.60%), and provides institutional shareholding trends over several quarters. Additionally, the article lists ETFs with holdings in LENZ Therapeutics.

LENZ Therapeutics, Inc. Revenue Breakdown – NASDAQ:LENZ

https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-segments/
This article provides a basic overview of LENZ Therapeutics, Inc. (NASDAQ: LENZ) on TradingView, focusing on accessing its financial data. It indicates the stock market status and directs users to various financial segments like statements, statistics, dividends, earnings, and segment performance. The content is primarily a navigation hub to financial information rather than an analysis itself.

LENZ Therapeutics (LENZ) 2024 Cantor Fitzgerald Global Healthcare Conference Summary

https://quartr.com/events/lenz-therapeutics-lenz-2024-cantor-fitzgerald-global-healthcare-conference_FeQ4lxFw
LENZ Therapeutics presented at the 2024 Cantor Fitzgerald Global Healthcare Conference, highlighting its once-daily eye drop for presbyopia. The company completed Phase III studies with an NDA filed, anticipating approval mid-next year and launch in the second half of 2025. The product demonstrated significant near vision improvement and high safety, targeting a $3 billion US market with a cash pay model and a strategic commercial launch plan.

LENZ|LENZ Therapeutics Inc|Price:5.030|Chg%:-0.310

https://www.tradingkey.com/markets/stocks/lenz/company
LENZ Therapeutics Inc. is a pre-commercial stage biopharmaceutical company focused on developing aceclidine-based eye drops for presbyopia. Their lead product, LNZ100, is a once-daily eye drop that was evaluated in a Phase III study. The article also lists company executives, their shareholdings, and institutional ownership data for LENZ Therapeutics.

LENZ Therapeutics (LENZ) Q1 2026 earnings summary

https://quartr.com/events/lenz-therapeutics-inc-lenz-q1-2026_FeQ4v1Jr
LENZ Therapeutics reported Q1 2026 revenue of $1.9 million, primarily from VIZZ product sales, with over 46,000 prescriptions filled since launch. While new patient adoption is growing, it is below target, prompting expanded sales force and DTC campaigns. The company is actively pursuing international expansion and expects its cash reserves to fund operations through to positive operating cash flow.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement